Tonix Pharma Collaborates With Massachusetts General Hospital For TNX-1900 In Binge Eating Disorder

  • Tonix Pharmaceuticals Holding Corp TNXP has announced an agreement with Massachusetts General Hospital to evaluate TNX-1900 (intranasal potentiated oxytocin) in a Phase 2 trial as a potential treatment for binge eating disorder. 
  • The Phase 2 clinical trial is expected to start in 2H of 2022.
  • TNX-1900 is also in development for the treatment of chronic migraine. It is expected to enter a Phase 2 potential pivotal clinical trial to prevent migraine headache in chronic migraineurs in 2H of 2022.
  • The planned investigator-initiated Phase 2 trial will be a randomized, double-blind, placebo-controlled study of 60 patients with binge eating disorder and obesity. 
  • Related: Tonix Pharma Inks Research Pact For Oxytocin In Eating Disorder.
  • The 8-week study will evaluate the efficacy and safety of TNX-1900 as a treatment for binge eating disorder and determine whether TNX-1900 reduces bingeing frequency and body weight in adults. 
  • TNX-1900 is based on a proprietary potentiated formulation of oxytocin and is currently being developed as a candidate for chronic migraine prophylaxis, insulin resistance treatment, and related conditions.
  • Price Action: TNXP shares are up 1.65% at $0.21 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!